Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuka, Taiga, Nakashita, Shunya, Yanagita, Kimihiko, Ario, Keisuke, Kawasoe, Hiroaki, Kawazoe, Seiji, Eguchi, Yuichiro, Mizuta, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548234/
https://www.ncbi.nlm.nih.gov/pubmed/28943609
http://dx.doi.org/10.3390/diseases3020068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548234/
https://www.ncbi.nlm.nih.gov/pubmed/28943609
http://dx.doi.org/10.3390/diseases3020068

Ejemplares similares